Full Press Release Details
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer.
IDYA
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer
Key Takeaway: IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer